The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

dashClinical provides instant payments that enhance trial completion and subject retention. Credit: PeopleImages/Shutterstock.com. Dash Solutions has introduced ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

The antibody is currently under development for hereditary angioedema treatment. Credit: Akimov Igor/Shutterstock.com. Astria Therapeutics has commenced the Phase III ORBIT-EXPANSE long-term study ...

The trial aims to determine the dosing interval, optimal dose and number of administrations for curing chronic hepatitis B. Credit: Gorodenkoff/Shutterstock.com ...

Enanta Pharmaceuticals reported that the Phase IIb trial failed to meet its primary endpoint. Image credit: viewimage / Shutterstock.com. Enanta Pharmaceuticals has seen its stock more than double, ...